Clinical Trial Update: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on polatuzumab vedotin in combination with standard chemoimmunotherapy in B-cell non-Hodgkin's lymphoma (Phase 1/2) completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lymphoma, Non Hodgkin | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-03